UPDATE: EKF Diagnostics Drops As Medicare Reimbursement For Selah Biomarkers Reduced
LONDON (Alliance News) - EKF Diagnostics Holdings PLC saw its shares drop on the AIM All-Share market Wednesday after the company said reimbursement by Medicare for Selah Genomic's drug metabolism genetic biomarkers panel, has been reduced after revisions by the Medicare Administrative Contractor Read More